Zacks: Brokerages Expect Evoke Pharma Inc (EVOK) to Post -$0.07 EPS

Share on StockTwits

Equities research analysts expect that Evoke Pharma Inc (NASDAQ:EVOK) will report earnings per share of ($0.07) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Evoke Pharma’s earnings. Evoke Pharma reported earnings of ($0.24) per share in the same quarter last year, which suggests a positive year over year growth rate of 70.8%. The business is scheduled to announce its next quarterly earnings report on Tuesday, November 13th.

According to Zacks, analysts expect that Evoke Pharma will report full year earnings of ($0.42) per share for the current financial year, with EPS estimates ranging from ($0.43) to ($0.40). For the next financial year, analysts expect that the company will post earnings of ($0.57) per share, with EPS estimates ranging from ($0.83) to ($0.31). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that cover Evoke Pharma.

Evoke Pharma (NASDAQ:EVOK) last announced its quarterly earnings data on Thursday, August 9th. The specialty pharmaceutical company reported ($0.14) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.16) by $0.02.

Several analysts have recently weighed in on the company. ValuEngine upgraded Evoke Pharma from a “sell” rating to a “hold” rating in a report on Thursday, August 2nd. HC Wainwright set a $9.00 price objective on Evoke Pharma and gave the company a “buy” rating in a report on Friday, August 17th. Finally, Zacks Investment Research downgraded Evoke Pharma from a “buy” rating to a “hold” rating in a report on Wednesday. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $6.69.

In related news, major shareholder Lvp Gp Iii, Llc bought 500,000 shares of Evoke Pharma stock in a transaction dated Monday, August 20th. The stock was acquired at an average cost of $2.35 per share, with a total value of $1,175,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 11.94% of the company’s stock.

Shares of Evoke Pharma stock traded up $0.02 during trading on Friday, hitting $2.59. The stock had a trading volume of 60,547 shares, compared to its average volume of 75,392. The firm has a market cap of $43.43 million, a price-to-earnings ratio of -3.12 and a beta of 1.47. Evoke Pharma has a fifty-two week low of $1.85 and a fifty-two week high of $4.09.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is in Phase 2b clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Featured Article: How Do You Calculate Return on Equity (ROE)?

Get a free copy of the Zacks research report on Evoke Pharma (EVOK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Evoke Pharma (NASDAQ:EVOK)

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply